TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02778009

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: iDEXA Scan
Description: Subjects will receive pre study and post study scans to assess body mass composition

Intervention type: RADIATION
Group type: OTHER
Intervention: iDEXA Scan
Description: Subjects will receive pre study and post study scans to assess body mass composition

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iDEXA Scan
Description: Subjects will receive pre study and post study scans to assess body mass composition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellness Lectures
Description: Subjects in the Fit Physician Arm will be required to attend monthly wellness lectures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Subjects in the Fit Physician Arm will be required to attend weekly exercise interventions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitor
Description: Subjects in the Fit physician arm and the activity monitor arm will receive activity monitors to assess their activity level throughout the academic year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity monitor
Description: Subjects in the Fit physician arm and the activity monitor arm will receive activity monitors to assess their activity level throughout the academic year
Study: NCT03052231

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: caremessage
Description: Central to the mobile health information service is the interactive and personalized text-based message system that delivers actionable and tailored health content to participants: office visit appointment reminders; medication adherence reminders; and general health education messages.
Study: NCT05935397

Intervention type: DEVICE
Intervention: percutaneous coronary intervention
Description: patients with CAD undergoing PCI with second generation DES
Study: NCT06755905

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment group
Description: Resection with sclerotherapy
Study: NCT06754215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Participate in focus group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in semi-structured interview

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Participate in feasibility study of intervention components

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study: NCT06753968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Right Hemicolectomy With Transrectal/transvaginal Specimen Extraction (NOSES)
Description: Transvaginal extraction, begins with the irrigation and disinfection of the vagina, followed by a transverse incision in the posterior fornix. The assistant then utilizes oval forceps to carefully extract the specimen bag through the incision, which is subsequently closed with continuous full-thickness sutures, using barbed sutures to ensure secure closure. Similarly, transrectal extraction begins with irrigation of the rectum using a dilute iodine solution, followed by a longitudinal incision along the anterior wall of the upper rectum. The specimen, along with the protective sleeve, is then removed using oval forceps, and the incision is closed with a continuous full-layer running suture once the specimen has been completely extracted.
Study: NCT00687271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6213
Description: MK-6213 160 mg for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6213
Description: MK-6213 160 mg for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin calcium
Description: atorvastatin calcium 20mg for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin calcium
Description: atorvastatin calcium 20mg for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for MK-6312 160 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-6312 160 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atorvastatin 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Atorvastatin 20 mg
Study: NCT02968173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palivizumab
Description: Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed to an epitope in the A antigenic site of the F (fusion) protein of RSV.
Study: NCT01073813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 100mg twice daily
Study: NCT06753968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Totally laparoscopic right hemicolectomy (TLRH)
Description: Totally laparoscopic right hemicolectomy (TLRH), which involves performing intracorporeal anastomosis and specimen extraction through a small abdominal incision, further enhances the benefits of minimally invasive surgery. In the TLRH group, following the stapled side-to-side anastomosis, a small horizontal incision is made about 2 to 3 cm above the symphysis pubis, at the junction of the pubic hairline, to allow for specimen removal.
Study: NCT03575052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, tablets, once daily by mouth (provided as two placebo tablets)
Study: NCT02423395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orphenadrine
Description: Orphenadrine in muscle cramps in cirrhotic patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calcium in muscle cramps in cirrhotic patients
Study: NCT03938350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT) Skills Training
Description: Standard DBT skills training is a comprehensive intervention for emotion dysregulation that includes four skills modules: (1) mindfulness skills; (2) emotion regulation skills; (3) interpersonal effectiveness skills; and (4) distress tolerance skills designed to target adaptive skills deficits that define emotion dysregulation. The sessions will be delivered virtually via a HIPAA-compliant video platform.
Study: NCT02589132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile-Thrive application
Description: Families receive standard of care plus the Mobile-Thrive application
Study: NCT02695550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-707
Study: NCT04124601

Intervention type: RADIATION
Group type: OTHER
Intervention: Chemoradiotherapy
Description: Capecitabine tablet with fractionated radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Capecitabine tablet with fractionated radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Infusion
Study: NCT04699318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B
Description: To release the pediatric hypospadias using Double Dartos Tubularized incised plate (TIP) Urethroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: To release the pediatric hypospadias using Single Dartos Tubularized incised plate (TIP) Urethroplasty
Study: NCT00890370

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Airway clearance technique

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Airway clearance technique

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Airway clearance technique

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Airway clearance technique

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Airway clearance technique
Study: NCT00246129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Campath
Description: Monoclonal antibody induction therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Monoclonal antibody induction therapy
Study: NCT02704026

Intervention type: OTHER
Intervention: Assesment of nutritional status and body composition
Description: At the time of enrollment and after 1 year, anthropometric measurements and assessment of body composition by bioelectrical impedance will be performed for each child

Intervention type: OTHER
Intervention: Assesment of nutritional status and body composition
Description: At the time of enrollment and after 1 year, anthropometric measurements and assessment of body composition by bioelectrical impedance will be performed for each child
Study: NCT03740737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Description: FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 12 µg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 µg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 µg, and the maximum daily dose was 24 µg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed.
Study: NCT03261713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality training is provided using Jintronix Rehabilitation software. A Kinect camera captures the movements of the participant using infrared technology and allows them to control an avatar, which interacts with an activity. Several games and activities are available to train standing balance (ex. slalom skiing), reaching (ex. planting seeds/harvesting tomatoes), stepping (ex. whack-a-mole), gentle strengthening (ex. knee extensions) and aerobic exercises (ex. marching on the spot). Game and activity difficulty can be increased by requiring more repetitions, or greater speed, distance and/or accuracy. Specific games and activities, and their parameters are customized for each participant. The exercise plan is performed 5 times a week for 6 weeks for 30 minutes at each session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control group are provided with an iPad which contains a selection of apps suited for memory (ex. memory card game), cognition (Sudoku, cross-word), visual tracking (word search) and fine motor skills (ex. writing, whack-a-mole). Participants are instructed to perform their exercise plan 5 times a week for 6 weeks for 30 minutes at each session.
Study: NCT02380885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCIT
Description: psychosocial group intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAFT
Description: psychosocial group intervention
Study: NCT00702338

Intervention type: DRUG
Intervention: corifollitropin alfa
Description: SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.

Intervention type: DRUG
Intervention: corifollitropin alfa
Description: SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.

Intervention type: BIOLOGICAL
Intervention: recombinant Follicle Stimulating Hormone (recFSH)
Description: Daily injections of SC recFSH (50 IU/75 IU) were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.

Intervention type: BIOLOGICAL
Intervention: human Chorion Gonadotropin (hCG)
Description: Daily injections of SC hCG injection were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.

Intervention type: BIOLOGICAL
Intervention: hCG Bolus injection
Description: Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.

Intervention type: BIOLOGICAL
Intervention: hCG Bolus injection
Description: Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.
Study: NCT00084409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01142388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study: NCT03059745

Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Single Port and Multi-Port approaches trans-laparoscopic approaches with or without the use of the daVinci Surgical Robotic System.
Study: NCT00516672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib oral tablet
Study: NCT01219426

Intervention type: OTHER
Intervention: Filling of three questionnaires
Description: The only intervention of the study was the completion of the three questionnaires, and of a mini-questionnaire assessing gender, age, and gambling activities.

Intervention type: OTHER
Intervention: Filling of three questionnaires
Description: The only intervention of the study was the completion of the three questionnaires, and of a mini-questionnaire assessing gender, age, and gambling activities.
Study: NCT00072280

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Given Slow intravenous (IV) push over 1-5 minutes, dose \< 1yr 0.025 mg/kg \> or = 1 yr 0.045 mg/kg (max dose 2.5 mg) on days 1,22,43 and 64

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV over 60 minutes, dose 25 mg/kg on days 1,22,43 and 64.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV over 1 hour, dose 3.3 mg/kg in normal saline (NS) 10 cc/kg (or to equal 0.4 mg/mL concentration) on days 1-5 of IE cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV over 1 hour, dose 60mg/kg in D5 1/4 NS 10 cc/kg IV on days 1-5 of IE Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV Push over 1 minute, dose 0.05 mg/kg (max dose 2 mg) on days 1,8,15,22,29,36,43,50,57 and 64

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Applied only when lesion is resectable. Surgery is the primary means of local control in this study and reasonable attempts at achieving clear margins with an envelope of normal tissue should be undertaken at the initial and/or subsequent resections.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Applied only when lesion is resectable. Surgery is the primary means of local control in this study and reasonable attempts at achieving clear margins with an envelope of normal tissue should be undertaken at the initial and/or subsequent resections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MESNA (mercaptoethane sulfonate)
Description: Given orally. Oral daily MESNA dose is equal to at least 60% of the daily cyclophosphamide dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV - Only use filgrastim if chemotherapy has been delayed or modified for hematologic toxicity, or if patient experiences a significant life-threatening toxicity due to bone marrow suppression
Study: NCT01142388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03763929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-Sodium Crocetinate
Description: In the study drug kit containing the experimental drug (TSC), TSC will be reconstituted with the Sterile Water for Injection (USP) supplied in the same kit. There will be an unblinded paramedic who will reconstitute and inject the TSC on the ambulance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study drug kit containing placebo (sterile saline for Injection) will be prepared and injected by the unblinded paramedic on the ambulance.
Study: NCT02701829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONTROL- Usual & Customary Health Fair Follow-up
Description: participating drivers may fall into 1 of 2 categories- Regular follow-up, or Urgent Follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Fair + TECH [Text Messaging + Home Blood Pressure Monitoring]
Description: all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors and have the mobile health text messaging intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heal th Fair + TECH [Text Messaging + Home Blood Pressure Monitoring] + Social Network Support (SNS)
Description: all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors for daily BP self-monitoring and text messaging, and they will receive the social network support intervention including an SNS guide for each SNS.
Study: NCT02612623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant tablets administered by mouth twice daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant tablets administered by mouth twice daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant tablets administered by mouth twice daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for gefapixant)
Description: Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks
Study: NCT03598023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cytal® Burn Matrix
Description: Cytal® Burn Matrix

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EZ-Derm® Porcine Xenograft
Description: EZ-Derm® Porcine Xenograft
Study: NCT02960711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ludipress, mg stereate, micronized hydrated silica, talcum
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ludipress, mg stereate, micronized hydrated silica, talcum
Description: Tablet
Study: NCT05750602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LIMICOL
Description: Suplementation with LIMICOL, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Suplementation with PLACEBO, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
Study: NCT03267082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic management of perforated appendicitis
Description: 1. Insertion of Ports~2. Exposure of the Appendix~3. peritoneal toilet and aspiration of pus after abdominal exposure~4. Isolation of Mesoappendicular Artery~5. Clipping and Dividing of the Artery~6. Application of 3 x Endoloops~7. Division of the Appendix~8. Retrieval of the Appendix in an Endobag
Study: NCT01448330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0911 / clopidogrel, aspirin
Description: combination tablet vs coadministration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP0911 / clopidogrel, aspirin
Description: combination tablet vs coadministration
Study: NCT03656692

Intervention type: DRUG
Group type: OTHER
Intervention: Acthar Gel
Description: Acthar gel for subcutaneous injection 80 units per mL (40 units per 0.5 mL)
Study: NCT03213002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine at 1500 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide at 150 mg/m2 - 200 mg/m2
Study: NCT01142388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01386385

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-conformal RT
Study: NCT00468481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate
Description: 0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drospirenone/Ethinylestradiol (Yaz)
Description: 0.020 mg ethinylestradiol with 3.0 mg drospirenone
Study: NCT02242682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Child passenger safety video
Study: NCT02582892

Intervention type: DRUG
Group type: OTHER
Intervention: Vit D
Description: 20 mg/day